# Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease

> **NCT02782741** · PHASE3 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 101 (actual)

## Conditions studied

- Glycogen Storage Disease Type II;Pompe's Disease

## Interventions

- **DRUG:** Avalglucosidase alfa (GZ402666)
- **DRUG:** Alglucosidase alfa (GZ419829)

## Key facts

- **NCT ID:** NCT02782741
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-02
- **Primary completion:** 2020-03-19
- **Final completion:** 2023-05-31
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2024-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02782741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02782741, "Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02782741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*